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Abstract 
Cartilage oligomeric matrix protein (COMP), a protective component of vascular 
extracellular matrix (ECM), maintains the homeostasis of mature vascular smooth muscle 
cells (VSMCs). However, whether COMP modulates the differentiation of stem cells towards 
the smooth muscle lineage is still elusive. Firstly, purified mouse COMP directly induced 
mouse embryonic stem cell (ESC) differentiation into VSMCs both in vitro and in vivo, while 
the silencing of endogenous COMP markedly inhibited ESC-VSMC differentiation. 
RNA-Sequencing revealed that Notch signaling was significantly activated by COMP during 
ESC-VSMC differentiation, whereas the inhibition of Notch signaling attenuated 
COMP-directed ESC-VSMC differentiation. Furthermore, COMP deficiency inhibited Notch 
activation and VSMC differentiation in mice. Through silencing distinct Notch receptors, we 
identified that Notch1 mainly mediated COMP-initiated ESC-VSMC differentiation. 
Mechanistically, COMP N-terminus directly interacted with the EGF11-12 domain of Notch1 
and activated Notch1 signaling, as evidenced by co-immunoprecipitation and mammalian 
two-hybrid assay. In conclusion, COMP served as a potential ligand of Notch1, thereby 
driving ESC-VSMC differentiation.  
 
Keywords: Embryonic stem cells; Vascular smooth muscle cells; COMP; Notch signaling 
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1. Introduction 
Embryonic stem cells (ESCs) with the feature of pluripotency have the potential to 
differentiate into vascular smooth muscle cells (VSMCs), which express specific cell markers, 
such as -smooth muscle actin (-SMA), smooth muscle protein 22 (SM22), calponin and 
smooth muscle myosin heavy chain (SM-MHC) and fine-tune vascular integrity and 
homeostasis [1, 2]. Thus, ESCs serve as a promising source of VSMCs in vascular tissue 
engineering, angiogenesis, and vasculogenesis and play a pivotal role in vascular injury repair 
[3]. The downstream signals of cell surface receptors including integrins, Notch and growth 
factor receptors (e.g., TGFR, PDGFR) [4, 5], as well as Nrf3-mediated transcriptional 
regulation [6], Nox4-derived ROS production [1] and HDAC- or miRNA-related epigenetic 
modulation [7], have been identified to mediate this differentiation process, although the 
mechanism of stem cell differentiation into the smooth muscle lineage is not fully understood.  
The extracellular microenvironment, composed of a variety of extracellular matrix (ECM) 
components, ECM-bound growth factors, receptors and proteases, is a crucial regulator of the 
cell fate of ESCs [8-11]. In particular, ECM proteins, including collagens, elastins, 
proteoglycans and glycoproteins, fine-tune cell differentiation and behavior via 
protein-protein complex interaction. Moreover, the constitution and stiffness of the ECM 
coordinately direct cell division and differentiation. Through recent proteomic analysis, more 
than 100 ECM proteins have been identified in human aortas and porcine stented coronary 
arteries, most of which are glycoproteins and proteoglycans with unknown functions [12, 13]. 
Nevertheless, only a few ECM proteins have been suggested to be involved in smooth muscle 
lineage specification. For example, vascular wall resident collagen IV and hyaluronan have 
been reported to direct ESC differentiation into SMCs [14, 15]. Exploring how ECM 
components mediate ESC differentiation towards the smooth muscle lineage would facilitate 
the development of new regenerative therapies for repairing injured VSMCs in vascular 
diseases.  
Cartilage oligomeric matrix protein (COMP), a 524 kDa pentameric noncollagenous 
glycoprotein, is a matricellular protein that is abundant in the cardiovascular system. Our 
recent studies have shown that COMP plays protective roles in maintaining mature VSMC 
homeostasis by interacting with various binding proteins (e.g., integrin 7 and BMP-2) [16, 
17]. COMP maintains the contractile phenotype of VSMCs and suppresses atherosclerotic 
neointima formation and VSMC calcification [16-18]. Here, we unexpectedly discovered that 
COMP may serve as a novel ligand of Notch1, thereby directly driving ESC differentiation 
towards the smooth muscle lineage.  
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2. Materials and methods  
2.1 Materials 
Recombinant platelet-derived growth factor-BB (PDGF-BB) (220-BB) was obtained 
from R&D (Flanders, NJ, USA), and transforming growth factor-β (TGF-β) (AF-100) was 
obtained from PeproTech Group Inc. (Chicago, IL, USA). Antibodies against COMP 
(ab28400), Notch1 (ab65297), SM α-actin (α-SMA) (ab119952), calponin (ab46794), and 
SM22α (ab10135) are from Abcam plc (Cambridge, UK). DAPT (orb65891) was purchased 
from Biorbyt (Cambridge, UK). Antibody against cleaved Notch1 (Val1744) was obtained 
from Cell Signaling Technology (Boston, MA, USA). Gelatin was obtained from Merck 
Millipore (Darmstadt, Germany). Heparin-agarose beads (H0402) were obtained from 
Sigma-Aldrich (St. Louis, MO, USA). Matrigel™ Basement Membrane Matrix (356234) was 
bought from BD Biosciences (San Diego, CA, USA).  
 
2.2 Cell Culture and ESC-VSMC Differentiation 
Mouse ESCs (ES-D3 cell line, CRL-1934) were obtained from ATCC Inc. (Manassas, 
VA, USA). ESCs were seeded at density of 2×10
5
 cells per 25 cm
2
 on mitomycin C (10 
µg/ml)-treated confluent mouse embryonic fibroblast (MEF) cell feeder in 0.1% gelatin 
(Millipore, Boston, MA, USA)-coated flasks and cultured in ESC medium including 
Dulbecco’s modified Eagle’s medium (DMEM) (Life Technologies, Carlsbad, FL, USA), 10% 
EmbryoMax fetal bovine serum (FBS) (Millipore, Boston, MA, USA), 10 ng/ml of leukemia 
inhibitory factor (LIF) (Millipore, Boston, MA, USA), 0.1 mM of 2-mercaptoethanol (2-ME) 
(Life Technologies, Carlsbad, FL, USA), 100 U/ml of penicillin (Life Technologies, Carlsbad, 
FL, USA), 100 µg/ml of streptomycin (Life technologies, Carlsbad, FL, USA) and 2 mM of 
glutamine (Life Technologies, Carlsbad, FL, USA). They were split at a ratio of 1:6 every 
other day and seeded at density of 2×10
5
 cells per 25 cm
2
. For ESC-VSMC differentiation, 
cell culture dishes were pre-coated with 0.5 ml of Tris-buffered saline containing various 
concentrations of gelatin, mouse collagen IV or mouse COMP per cm
2
 area at room 
temperature overnight. Undifferentiated ESCs (2×10
5
 cells per 60 mm dish) were seeded on 
mouse collagen IV (10 µg/ml)- or purified-COMP-coated dishes in differentiation medium 
(DM) containing α-minimal essential medium (Life Technologies, Carlsbad, FL, USA) 
supplemented with 10% FBS, 0.05 mM of 2-ME, 100 U/ml of penicillin, 100 µg/ml of 
streptomycin and 2 mM of glutamine. DM was refreshed every day after the second day of 
differentiation. The cells were cultured in DM for 3-7 days, after which they were harvested 
and further analyzed. 293A cells and COS-7 cells from ATCC were maintained and passed in 
high-glucose DMEM supplemented with 10% FBS, 100 U/ml of penicillin and 100 μg/ml of 
streptomycin in an incubator with a 5% CO2/water-saturated atmosphere at 37°C. 
 
2.3 Recombinant COMP Expression in 293A Cells and COMP Purification 
The plasmid pcDNA3.1 encoding cDNA of full-length mouse COMP was constructed 
and transfected into 293A cells using of Lipofectamine 2000 (Life Technologies, Carlsbad, 
CA, USA). Stably transfected cells were selected with 750 mg/L G418. For COMP 
purification, stably transfected 293A cells were incubated in serum-free Opti-MEM 
(GIBCO, Rockford, CA, USA) with G418 (250 mg/L) for 48 hours. The conditioned 
medium was incubated with heparin-agarose beads (Sigma-Aldrich, St. Louis, MO, USA) 
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equilibrated with Tris-buffered saline containing 2 mM of CaCl2 for binding overnight at 
4°C with gentle agitation. After five-time washes, COMP was eluted with 0.75 M NaCl 
(buffered in 10 mM Tris, pH 7.5) containing 2 mM of CaCl2. The purified mouse COMP 
protein was verified by western blot analysis, while the purity of COMP was more than 98% 
as identified in SDS-PAGE followed by Coomassie Brilliant Blue G250 staining (Figure 
S1). [17, 19, 20] 
 
2.4 Western Blotting 
Cells (1×10
6
 cells per sample) subjected to different treatments or aortic tissue dissected 
from 8-week old mice were lysed in RIPA buffer and prepared for extraction of whole-cell 
protein samples. Then, equal amounts of total protein (50-100 g) per sample were resolved 
using 8% or 10% SDS-PAGE and transferred onto nitrocellulose membranes. The blots were 
subsequently incubated with primary antibodies (SM22α, -SMA, calponin, GAPDH, COMP, 
cleaved Notch1 and Notch1; 1:1000) and IRDye-conjugated secondary antibodies (1:10000, 
Rockland Inc., Gilbertsville, PA, USA). The fluorescence signal was detected with an 
Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE, USA), and the band 
density was analyzed using NIH Image J software. 
 
2.5 Quantitative PCR Analysis  
Total RNA was extracted from 5×10
5
 cells per sample by using Trizol reagent (Life 
Technologies, Carlsbad, CA, USA), and equal amounts (2 μg) were reverse transcribed to 
cDNA by using 5× All-In-One RT MasterMix (TransGen Biotech, Beijing, China). 
Quantitative PCR amplification was performed using a QuantStudio 3 Real-Time PCR 
System (Stratagene Corp., La Jolla, CA, USA). SYBR Green 2× PCR mix (TransGen Biotech, 
Beijing, China) was used according to the manufacturer’s instructions. The data were 
normalized to the internal control 18S. The primer sequences for the target genes are listed in 
Table S1.  
 
2.6 Immunofluorescent Staining 
Cells or tissue slides were first fixed by using 4% paraformaldehyde for 10 minutes, then 
incubated with rabbit anti-calponin or goat anti-SM22 antibody overnight at 4°C. 
Subsequently, Alexa Fluor 488-conjugated donkey anti-rabbit IgG (1:400) (Life Technologies, 
Carlsbad, FL, USA) or Alexa Fluor 555-conjugated donkey anti-goat IgG (1:400) (Life 
Technologies, Carlsbad, FL, USA) antibody was applied, and the samples were incubated for 
1 hour. Nuclei were stained with Hoechst 33342 for 1 minute. As a negative control, rabbit or 
goat IgG was applied instead of the primary antibodies. The fluorescence signal was 
visualized by confocal laser scanning microscopy (Leica Microsystems, Wetzlar, Germany). 
 
2.7 Cell Contraction Assay 
A Cell Contraction Assay kit (CBA-021) was purchased from Cell Biolabs Inc. (San 
Diego, CA, USA). The contractile ability of the cells was evaluated according to the 
manufacturer’s instructions. Cells were harvested and resuspended in culture medium at 
density of 2×10
6
 cells/ml. A collagen lattice was prepared by mixing cell suspension and 
ice-cold collagen gel solution in a volume ratio of 1:4. Then, 0.5 ml of the cell-collagen 
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mixture per well was added to a 24-well plate and incubated for 1 hour at 37°C. After 
collagen polymerization, 1.0 ml of culture medium was added on top of each collagen gel 
lattice. Twenty-four hours later, the 24-well plate was photographed, and the size of the 
collagen gel in each well was measured with NIH Image J software.  
 
2.8 Animal Preparation 
All animal studies and experimental procedures in the present study were approved by 
the Institutional Animal Care and Use Committee (IACUC) of the Peking University Health 
Science Center and were performed in compliance with the ethical guidelines of that 
institution. Eight-week old C57BL/6J mice (Vital River, Beijing, China) were used for the 
in vivo ESC-VSMC differentiation assay. COMP
−/−
 mice on a C57BL/6J background were 
kindly provided by Professor Äke Oldberg (Department of Cell and Molecular Biology, 
University of Lund, Sweden) [21]. COMP
−/−
 mice and their wild-type (WT) littermates at 8 
weeks old were euthanized by CO2 for aorta isolation. 
 
2.9 In vivo ESC-VSMC Differentiation 
ESCs (1×10
6
 cells in 50 µl of MEM) were labeled with CM-DiI dye (Life Technologies, 
Carlsbad, FL, USA), mixed with 150 µl of Matrigel (BD Biosciences ,San Diego, CA, USA) 
containing PDGF-BB (10 ng/ml) or COMP (10 g/ml ) at 4°C, and then subcutaneously 
injected into C57BL/6 mice (male, 8 weeks old). After 13 days, the mice were euthanized, 
and the implants (Matrigel plugs) were embedded in OCT compound and frozen in liquid 
nitrogen. Sections (8 µm thick) were cut every 40 µm along the longitudinal axis of each 
Matrigel plug. In total, 8 interval sections were collected from each Matrigel plug for further 
immunofluorescent staining.  
 
2.10 RNA Sequencing 
Total RNA was isolated from undifferentiated ESCs or COMP-differentiated (3 days) 
ESCs (1×10
6
 cells per sample) using GeneJET RNA Purification Kit (K0731, Thermo 
Scientific Inc., Rockford, CA, USA). After extensive quality control, 1 μg of RNA was used 
for generation of sequencing library using the TruSeq RNA Library Prep Kit V2 
(RS-122-2002, Illumina) according to manufacturer’s instructions. All libraries were 
sequenced on the NextSeq500 sequencer (FC-404-2005, Illumina) using the 35nt paired-end 
sequencing protocol. After sequencing, reads were aligned to genomes of mm9 by Subread (R 
version 1.24.2).  
Uniq reads were kept and assigned to in-build refseq gene annotation of Rsubread using 
feature Counts. Differential analysis was conducted with Limma. Genes with fold change 
greater than 2 and FDR q value less than 0.05 were taken as significantly differentially 
expressed genes. 
 
2.11 Lentivirus Packaging 
Mouse COMP shRNA lentivirus were packaged as previously described [18]. The 
sequence of the mouse COMP shRNA was as follows: 
TGCTGTTGACAGTGAGCGCGAAGAATGACGATCAGAAAGATAGTGAAGCCACAGA
TGTATCTTTCTGATCGTCATTCTTCTTGCCTACTGCCTCGGA. 
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Mouse Notch1/2/3 shRNA lentivirus were packaged using the “all-in-one” system. 
Briefly, a DNA oligo encoding Notch1/2/3 shRNA or negative control shRNA (SHC016) was 
designed via the RNAi consortium collection (MISSION® shRNA, www.sigmaaldrich.com). 
The DNA fragment was cloned into the pLKO vector. Then, the created lentivirus plasmids 
were co-transfected with virus package vectors including pLP1 and pLP2 into 293T cells by 
use of Lipofectamine 2000 (Invitrogen, Eugene, OR, USA). The medium was changed after 6 
hours. Following 48 hours of culture, supernatant was collected as lentivirus stock for further 
infection of ESCs.  
Dominant-negative MAML fragment (dnMAML, aa 13-74) fused with GFP 
(dnMAML-GFP) and COMP N terminus (aa 1-83) inserted with Flag-tag following the signal 
peptide (aa 1-19) (COMP sig-Flag-N terminus) overexpression lentivirus were packaged 
using a Gateway Technology kit following the manufacturer’s instruction (Invitrogen, Eugene, 
OR, USA).  
The Notch shRNA oligo sequences are presented in Table S2, while the primers for 
subcloning dnMAML-GFP and COMP sig-Flag-N-terminus are referred to Table S3. 
 
2.12 Notch Pathway-responsive Luciferase Reporter Assays 
The plasmids, including pcDNA3.1-Notch1, pcDNA3.1-Jagged1 and pGL3-4×CBF1-luc, 
were generously donated by Dr. Tao Wang from the University of Manchester, United 
Kingdom [22]. The JetPEI DNA transfection reagent (Polyplus-transfection, Strasbourg, 
France) was applied to transfect 293A cells with pcDNA3.1-Notch1, pGL3-4×CBF1-luc and 
pcDNA3.1-β-galactosidase together with pcDNA3.1-COMP, pcDNA3.1-Jagged1 or 
pcDNA3.1 vector. Forty-eight hours after transfection, transfected cells were harvested for 
measurement of luciferase activity using a Luciferase Assay System (Promega, Madison, MI, 
USA) according to the manufacturer’s instructions. Meanwhile, the activity of β-galactosidase 
was evaluated via the ortho-Nitrophenyl-β-galactoside assay. Activation of the Notch pathway 
was represented as relative luminescence units normalized to β-galactosidase activity. 
 
2.13 Co-immunoprecipitation 
    COMP-induced differentiated ESCs or plasmid-transfected COS-7 cells confluent in one 
100 mm dish were lysed and then incubated with antibodies (1 g per sample in 500 l 
volume) against COMP, Notch1 or Flag-tag before being immunoprecipitated with protein 
A/G agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The precipitated 
proteins were resolved using 10% SDS-PAGE and then incubated with antibodies against 
Notch1 or COMP. Rabbit or mouse IgG served as a negative control according to the species 
of primary antibodies. 
 
2.14 Mammalian Two-hybrid Assay 
Fragments encoding serial functional domains of human Notch1 EGF repeats [EGF1-10 
(aa 20-410), EGF11-20 (aa 412-789), EGF21-30 (aa 791-1181), EGF31-36 (aa 1183-4278), 
EGF11-12 (aa 412-488), EGF13-14 (aa 489-563), EGF15-17 (aa 564-664) and EGF18-20 (aa 
665-789)] were amplified by PCR and subcloned into pBIND vector. cDNA inserts encoding 
the mouse COMP N-terminal domain (aa 1-83) were subcloned into the pACT vector [18]. 
293A cells were cotransfected with the target and bait constructs together with the luciferase 
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reporter plasmid pG5luc at a ratio of 1:1:1. Forty-eight hours after transfection, the cells were 
harvested, and cell lysates were used for luciferase activity assays with the Dual-Luciferase 
Reporter Assay System (Promega, Madison, WI, USA). The primers for subcloning the 
Notch1 EGF repeat fragments are provided in Table S3. 
 
2.16 Statistical Analysis  
All the results of the experimental studies were expressed as the mean ± SEM. Statistical 
analysis was performed using GraphPad Prism 6.0 software (GraphPad Software, San Diego, 
CA, USA). For the statistical comparisons, we first evaluated whether the data were normally 
distributed. Then, the Brown-Forsythe test was used to check for similar variances among 
normally distributed data, after which we used Student’s t-test for pairwise comparisons or 
ANOVA for comparisons of more than two groups if the test for similar variances was passed. 
In all cases, statistical significance was concluded if the two-tailed probability was less than 
0.05. Details of statistical analysis for each experiment are presented in the corresponding 
figure legends. 
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3. Results 
3.1 Purified COMP Directs ESC Differentiation into VSMCs in vitro and in vivo 
To explore the role of COMP in ESC differentiation, we first purified COMP protein from 
293A cells stably overexpressing mouse COMP and validated the purity of COMP protein in 
SDS-PAGE through Coomassie Brilliant Blue G250 staining (Supplemental Fig. 1). Then we 
seeded the mouse ESC line D3 on plates coated with 0.5 ml/cm
2
 of Tris-buffered saline 
containing various concentrations of purified COMP protein (5 μg/ml, 10 μg/ml, 20 μg/ml) or 
collagen IV (10 μg/ml) and cultured the D3 cells in the absence of leukemia inhibitory factor for 7 
days consecutively. Consisted with previous reports that collagen IV directly induced ESC 
differentiation into VSMCs [15], ESCs plated on collagen IV exhibited markedly elevated protein 
levels of VSMC markers (-SMA, calponin and SM22) (Fig. 1A). Similarly, COMP coating 
dose-dependently upregulated the protein expression of VSMC markers (-SMA, calponin and 
SM22) (Fig. 1A). Accordingly, COMP (10 μg/ml) time-dependently upregulated the VSMC 
contractile apparatus at both the protein and mRNA levels (Fig. 1B and Supplemental Fig. 2A). 
Especially, COMP significantly upregulated smoothelin, the gene specifically expressed in VSMCs 
rather than myofibroblast [23, 24], excluding the directed differentiation towards myofibroblast. 
By contrast, COMP did not direct ESC differentiation into endoderm (SOX17, FOXA2 and 
MIXL1), ectoderm (ZIC1 and SOX1), non-VSMC mesoderm lineages (cardiomyocytes: RYR2 
and SERCA2a; endothelial cells: CD31, CD144 and CD34) or other mesenchymal lineages 
(adipocytes: DKL1; osteoblasts: RUNX2 and OSX1) (Supplemental Fig. 2B-F). 
Immunofluorescent staining further verified the mature differentiated VSMC phenotype, 
characterized by high expression of calponin and SM22 (Fig. 1C-D). Functionally, a collagen 
contractile assay revealed that differentiated cells displayed contractility, which was comparable 
with that of PDGF-BB-induced differentiated VSMCs, whereas no contraction was observed in 
non-differentiated ESCs (Fig. 1E). To further confirm the effect of COMP in vivo, we 
subcutaneously injected C57BL/6J mice with Matrigel including DiI-labelled ESCs and purif ied 
COMP protein (10 g/ml) (Fig. 1F). Similar to PDGF-BB, COMP induced abundant expression of 
calponin and SM22  after 14 days in differentiated cells in Matrigel injected into mice, indicating 
the differentiation towards VSMCs in vivo (Fig. 1G and Supplemental Fig. 2G). Together, purified 
COMP is sufficient to drive ESC differentiation into VSMCs both in vitro and in vivo. 
 
3.2 COMP is Necessary for ESC Differentiation into VSMCs  
We next asked whether the endogenous COMP was involved in the differentiation into 
VSMCs. We applied three established differentiation systems, including collagen IV [5] (Fig.   
2A), PDGF-BB [25] (Fig. 2B) and TGF- [26] (Fig. 2C) induction for 7 days, to detect the 
protein expression of COMP at different time points. As a result, COMP was 
time-dependently upregulated in all three differentiation processes. Then, we silenced COMP 
by infection of COMP shRNA lentivirus into ESCs. Interestingly, COMP silencing 
significantly inhibited collagen IV- and PDGF-BB-induced VSMC differentiation as 
evidenced by reduced -SMA, calponin and SM22 expression at both protein and mRNA 
levels (Fig. 2D-E and Supplemental Fig. 3). Thus, endogenous COMP also plays a critical 
role in the differentiation of ESCs into VSMCs.  
 
3.3 Notch Signaling Mediates COMP-induced ESC Differentiation into VSMCs  
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To identify how COMP guided ESC differentiation towards VSMCs, we performed 
comparative RNA-Sequencing between ESCs and COMP-induced differentiated cells at day 3, 
the early stage of the differentiation process (Supplemental Fig. 4A). As the results, COMP 
upregulated 1,160 genes mainly related to pathways in cancer, Rap1 signaling pathway and 
Ras signaling pathway, but downregulated 898 genes including measles, osteoclast 
differentiation, toxoplasmosis, etc. (Fig. 3A and Supplemental Fig. 4B-C). The signaling 
activation of integrin, TGF, PDGF-BB, and Notch have been reported to mediate 
ESC-VSMC differentiation [7]. Interestingly, COMP greatly upregulated the expression of 
genes related to Notch signaling rather than the genes involved in the activation of other 
signals (Fig. 3B). Further real-time PCR analysis validated the upregulation of genes related 
to Notch signaling (Supplemental Fig. 4D). Canonical Notch signaling is initiated by ligand 
binding that leads to intramembrane proteolysis by a -secretase complex and releases the 
intracellular domain of Notch (NICD). Upon Notch activation, NICD forms a transcriptional 
complex with CSL/RBP-J and Mastermind-like (MAML) proteins and subsequently activates 
the transcription of Notch target genes, e.g., Hes1, Hey1 and Hey2 [27]. Indeed, COMP 
markedly enhanced the expression of these target genes at various time points during 
differentiation (Supplemental Fig. 5A). Conversely, COMP silencing during the process of 
collagen IV-induced differentiation repressed the induction of Notch target genes expression 
(Supplemental Fig. 5B). Overall, these results showed that COMP activates Notch signaling.  
We next wondered whether Notch signaling mediated COMP-directed differentiation. 
Firstly, the γ-secretase inhibitor DAPT was applied to inhibit Notch signaling (Supplemental 
Fig. 6A). As shown in Fig. 3C-D and Supplemental Fig. 6B, DAPT application significantly 
inhibited COMP-evoked ESC-VSMC differentiation and cell contractility. Moreover, we 
created a dominant-negative MAML (dnMAML) lentivirus encoding a GFP-fused N-terminal 
NICD-binding domain of Mastermind-like1 (MAML1) that blocks MAML1-mediated 
recruitment of coactivators and downstream transcriptional activation of all Notch receptors 
[28]. Similarly, ESCs infected with the lentivirus encoding dnMAML exhibited inhibition of 
Notch signaling (Supplemental Fig. 6C) and COMP-induced ESC-VSMC differentiation (Fig. 
3E and Supplemental Fig. 6D). Thus, COMP-activated Notch signaling mediates the 
differentiation of ESCs towards VSMCs. In accordance, COMP deficiency markedly 
attenuated VSMC contractile apparatus as well as cleaved Notch1 (indicating the activation of 
Notch1), Hes1, and Hey2 expression in the aortas compared with those of WT mice (Fig. 3F 
and Supplemental Fig. 7), indicating that COMP activated Notch signaling and induced 
VSMC differentiation in vivo. 
 
3.4 COMP Directly Activates Notch1 signaling 
The Notch family of cell surface receptors consists of four members, Notch1-4 [29, 30]. 
As previously reported, Notch1-3, but not Notch4, regulate VSMC development and 
differentiation [31-34]. To further verify which Notch member is the main contributor to the 
effect of COMP, we separately infected ESCs with lentivirus encoding Notch1, Notch2 or 
Notch3 shRNA (Supplemental Fig. 8). Only Notch1 silencing blocked COMP-induced 
upregulation of VSMC markers expression, whereas the silencing of Notch2 and Notch3 
displayed no effect (Fig. 4A). To further identify the specific effect of COMP on Notch1, we 
measured cleaved Notch1 by western blot. Interestingly, COMP induced the elevation of 
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cleaved Notch1 as early as 6 to 24 hours of treatment in ESCs (Fig. 4B). Meanwhile, the 
expression of Notch1 and its 5 classic ligands displayed no change during 24-hour stimulation 
(Supplemental Fig. 9), indicating that COMP did not transcriptionally regulate Notch1 or its 
ligands to activate Notch1 signaling in the short term. Moreover, we applied a CBF1 response 
luciferase reporter system in 293A cells to further evaluate the effect of COMP on Notch1 
activation. Similar to Jagged1, a canonical ligand of Notch1, COMP dose-dependently 
enhanced luciferase reporter transcription and activated Notch1 signaling (Fig. 4C). Moreover, 
the overexpression of COMP also increased the cleavage of Notch1 in 293A cells (Fig. 4D). 
Meanwhile , the mRNA levels of Notch1 and its ligands were not altered by COMP 
(Supplemental Fig. 10). These results suggest that COMP directly and rapidly activates 
Notch1 signaling independently of transcriptional regulation. To further verify the specificity 
of direct effect of COMP on Notch1 activation in the process of ESC-VSMC differentiation, 
we applied another differentiation induction reagent collagen IV in the CBF1 response 
luciferase reporter system and found that collagen IV did not directly activate Notch1 
signaling, implying the specific effect of COMP on directly activating Notch1 (Fig. 4E).  
 
3.5 COMP Directly Interacts with Notch1 
To further explore how COMP activated Notch1, we first performed a 
co-immunoprecipitation assay on COMP-induced differentiated VSMCs and COS-7 cells 
overexpressing Notch1 and COMP respectively. In both types of cells, Notch1 was similarly 
immunoprecipitated with COMP by anti-COMP antibody but not by rabbit IgG. Inversely, 
COMP was also exclusively immunoprecipitated with Notch1 by anti-Notch1 antibody (Fig. 
5A-B). Next, four domains of COMP including the N-terminal domain [N; aa 1-83], the 
epidermal growth factor repeat domain [EGF; aa 84-261], the type III repeat domain [type III; 
aa 266-520] and the C-terminal domain [C; aa 521-755] were subcloned into separate 
Flag-CMV plasmids (Fig. 5C). COS-7 cells overexpressing Notch1 and various Flag-tagged 
domains of COMP were subjected to co-immunoprecipitation using anti-Flag antibody. We 
found that Notch1 was specifically immunoprecipitated by the Flag-tagged N-terminal 
domain but not by other COMP fragments (Fig. 5D), indicating that COMP interacted with 
Notch1 through its N-terminus. In turn, we applied a mammalian two-hybrid assay to identify 
the COMP binding domain of Notch1. Since the EGF domain of Notch1 is the usual binding 
site for its extracellular ligand proteins [35], we constructed pBIND plasmids containing the 
following distinct fragments of the Notch1 EGF domain: aa 20 to 410 (EGF1-10), aa 412 to 
789 (EGF11-20), aa 791 to 1181 (EGF21-30), and aa 1183 to 1426 (EGF31-36) (Fig. 5E). 
These pBIND plasmids were individually cotransfected into 293A cells along with a pACT 
vector encoding the COMP N-terminal domain. As shown in Figure 5F, cells transfected with 
the EGF11-20 domain exhibited the highest luciferase activity compared with other EGF 
domains of Notch1, indicating that EGF11-20 contains the potential binding domain of 
COMP. We further defined the binding motif of Notch1 by subcloning the EGF11-12, 
EGF13-14, EGF15-17 and EGF18-20 domains (Fig. 5E), and found that EGF11-12 mediated 
COMP interaction with Notch1 (Fig. 5G). Thus, COMP binds to the EGF11-12 domain of 
Notch1 through its N-terminal domain.  
 
3.6 The N-terminal Domain of COMP is Sufficient to Activate Notch1 Signaling and 
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Guide ESC Differentiation towards VSMCs 
We next asked whether the N-terminal domain of COMP alone could exhibit effects 
comparable to those of COMP in directing Notch1 activation and ESC-VSMC differentiation. 
We infected ESCs with control lentivirus or lentivirus encoding Flag-N-terminal domain, and 
further validated the N-terminus was overexpressed and extracellularly secreted by infected 
cells (Supplemental Fig. 11A-B). As expected, Flag-N-terminal domain overexpression 
significantly increased cleaved Notch1 and upregulated Notch1 target genes expression on 
day 7 during the differentiation process, indicating the activation of Notch1 signaling (Fig. 
6A-B). Meanwhile, overexpression of Flag-N-terminal domain alone induced ESC-VSMC 
differentiation, which was comparable to the effect of COMP induction (Figure 6C-E and 
Supplemental Fig. 11C). Thus, the N-terminal fragment of COMP independently activates 
Notch1 signaling and induces the differentiation of ESCs into VSMCs.  
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4. Discussion 
In the present study, we identified a novel role of the ECM protein COMP in dictating 
ESC differentiation into VSMCs. Mechanistically, COMP may serve as a novel Notch1 ligand 
to directly activate Notch1 signaling. COMP-driven ESC-VSMC differentiation may provide 
significant prospects for new regenerative therapies to promote the recovery of impaired 
VSMCs, as well as for understanding the pathogenesis of vascular diseases.  
Our major finding is that COMP is attributable to the ECM microenvironment for 
ESC-VSMC differentiation during development dependent on Notch1 signaling. Especially, 
not only exogenous COMP protein, but endogenous COMP is also involved in this process. 
We found that endogenous COMP was upregulated during the differentiation of stem cells 
into SMCs, in accordance with previous microarray data [4], whereas silencing endogenous 
COMP inhibits ESC-VSMC differentiation induced by collagen IV or PDGF-BB, indicating 
that endogenous COMP is generally essential for ESC-VSMC differentiation. ESC 
differentiation towards the smooth muscle lineage not only regulates vascular development 
but also contributes to the postnatal pathogenesis of vascular diseases. Although COMP
-/-
 
mice are viable and exhibit no significant abnormality of vascular development, postnatal 
COMP
-/-
 VSMCs exhibited a decreased VSMC contractile apparatus and reduced contractility 
in the absence of pathological stimuli, and COMP
-/-
 mice are more susceptible than WT mice 
to atherosclerotic neointima formation and medial calcification [16-18, 36, 37]. Herein, we 
found that COMP deficiency attenuated the VSMC contractile apparatus in aortas as well.  
Taken together, COMP deficiency significantly retarded ESC-VSMC differentiation, it is 
conceivable that the absence of COMP at least partially impaired ESC differentiation towards 
the smooth muscle lineage during the prenatal stage. 
Moreover, both silencing of endogenous COMP and COMP deficiency exhibited the 
attenuated Notch activation during ESC-VSMC differentiation in vitro and in postnatal aortas 
in vivo, respectively. In mammals, there are four Notch receptors (Notch1-4) and five 
canonical ligands (Jagged1 and 2, Delta-like 1, 3, and 4) [27]. Notch signaling plays an 
essential role in vascular development and postnatal arteriogenesis. Human Notch genes are 
linked to various vascular genetic diseases, such as Alagille syndrome [38], Adams-Oliver 
syndrome [39] and CADASIL [40]. In particular, Notch1-3 and Jagged1 have been identified 
as predominant during the development and differentiation of VSMCs [34, 41, 42]. Inhibition 
of Notch signaling by DAPT attenuates stem cell–VSMC differentiation in vitro [4]. Together 
with our finding that endogenous COMP silencing inhibits Notch activation and ESC-VSMC 
differentiation, we speculated that endogenous COMP-Notch pathway may play a critical role 
in ESC-VSMC differentiation. Although Notch receptors may have some functional 
redundancy, they cannot replace one another at least due to their spatial and temporal 
expression. Notch2 and Notch3 are the predominant isoforms in mature VSMCs, which exhibit 
a comparable low level of Notch1 expression [40]. Especially, Notch2 is indispensable in 
VSMCs of large-caliber vessels, while Notch3 play a major role in VSMCs of smaller caliber 
vessels lacking of Notch2 expression [33, 43]. In current study, we explored that 
Notch1-related signals rather than Notch2/3-related signals mediated COMP-induced 
ESC-VSMC differentiation. Thus, Notch2/3 may contribute to the late/mature stage of 
ESC-VSMC differentiation when Notch1 turns into a low level of expression. To confirm this 
speculation needs further investigation. 
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Besides activating Notch1 signaling, another interesting finding of current study is that 
COMP is a non-canonical ligand of the Notch1 receptor. COMP directly associates with and 
activates Notch1 to induce the differentiation of ESCs into SMCs, without altering the 
expression of other canonical ligands. By using co-immunoprecipitation and mammalian 
two-hybrid assays, we identified the EGF11-12 domain on the extracellular motif of Notch1 
as the binding site of COMP; this domain is also responsible for the binding of canonical 
ligands (e.g., Jagged1 and DLL4) to Notch1 [44]. To further clarify whether COMP directly 
or indirectly activated Notch1 by affecting the interaction of Notch1 with other canonical 
ligands, we assessed Notch1 activation by using a luciferase assay and western blot analysis  
in the exogenous transfection cell system. Our data suggested that COMP did not significantly 
affect or even exhibit a trend toward attenuating Jagged1 activation of Notch1 (data not 
shown). Moreover, other differentiation inducer, such as collagen IV, was not able to directly 
activate Notch1, indicating the specific role of COMP in Notch1 activation (Figure 5F). Thus, 
COMP is a novel non-canonical Notch1 ligand. Mice with complete blockage of Notch 
signaling by knock-in of dnMAML in neural crest cells exhibited suppressed VSMC 
development and differentiation [32]. Loss of global Notch1 function results in early 
embryonic lethality due primarily to a vascular defect [45]. Herein, we discovered that 
COMP
-/-
 mice exhibited the downregulation of VSMC contractile apparatus in aortas as well 
as the decreased activation of Notch1, implying that COMP might serve as a novel agonist of 
Notch1 in regulation of VSMC differentiation in vivo. Interestingly, COMP
-/-
 mice do not 
display the abnormality in vascular development as existed in mice with Notch1 inactivation , 
indicating that Notch1 signaling does not only mediate COMP effects on VSMC 
differentiation, but also might be involved in other process in vascular development. 
Moreover, Notch1 canonical ligand Jagged1 also directed stem cell-VSMC differentiation [4]. 
Further comparison of COMP and canonical ligands in Notch1 activation may favor to 
explain the different phenotypes of COMP
-/-
 mice and Notch1
-/-
 mice. 
Notably, several non-canonical Notch ligands have been identified in mammals, 
including integral membrane-bound and glycosylphosphatidylinositol (GPI)-linked proteins 
(e.g., Delta-like 1, contactin 1), the ECM protein CCN3, thrombospondin (TSP)-2 and TSP-4 
[29, 46-48]. COMP belongs to the TSP matricellular protein family and is also known as 
TSP-5. Our previous studies and others have identified several proteins that bind to COMP 
and specifically mediate its effects in various physiological and pathological conditions [49]. 
In the cardiovascular system, COMP binds to thrombin via EGF repeats [50], BMP-2 via type 
III repeats [16] and integrin β1 and β3 via the C-terminal domain [18, 51] and subsequently 
fine-tunes hemostasis, vascular calcification, dilated cardiomyopathy and atherosclerosis, 
respectively. Herein, we further verified that the N-terminal domain of COMP could mimic 
the inducible effect of COMP in ESC differentiation into VSMCs, which is favorable to the 
development of new regenerative therapies to repair injured VSMCs in vascular diseases. 
Taken together, COMP is a potential Notch1 receptor and drives ESC differentiation 
towards the smooth cell lineage through directly activating Notch1 signaling. Thus, COMP 
may be potentially and therapeutically applied in vascular regeneration to recover the injured 
VSMCs in vascular diseases. 
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Figures and Figure Legends 
Fig. 1. COMP directly induces ESC differentiation into VSMCs. Cell culture dishes were 
pre-coated with 0.5 ml of Tris-buffered saline containing various concentrations of mouse 
collagen IV or mouse COMP per cm
2
 area at room temperature overnight. Undifferentiated 
ESCs (2×10
5
 cells per 60 mm dish) were seeded on mouse-collagen IV (10 µg/ml)- or 
purified-mouse-COMP-coated dishes in differentiation medium. (A) Representative western 
blot analysis and quantification of -SMA, calponin and SM22α expression in 
undifferentiated ESCs and ESCs cultured for 7 days on dishes coated with different doses of 
COMP or collagen IV (Col IV). GAPDH was used as the internal control. Data are presented 
as the mean ± SEM from three independent experiments. *P<0.05 vs. control. One-way 
ANOVA followed by the Dunnett’s multiple comparisons test. (B) Representative western 
blot analysis and quantification of -SMA, calponin and SM22α expression in 
undifferentiated ESCs and ESCs seeded on COMP (10 µg/ml)-coated plates for various 
periods. GAPDH was measured as the internal control. Data are presented as the mean ± SEM 
from three independent experiments. *P<0.05 vs. 0 day. One-way ANOVA followed by the 
Dunnett’s multiple comparisons test. (C-D) Immunofluorescent staining of calponin (C) and 
SM22 (D) in undifferentiated ESCs and ESCs seeded on COMP (10 g/ml)-coated plates 
for 7 days. Scale bar, 20 m. (E) ESCs with or without 7-day treatment of COMP (10 g/ml) 
or PDGF-BB (10 ng/ml) were harvested and mixed with ice-cold collagen gel solution in a 
volume ratio of 1:4. Twenty-four hours after collagen polymerization, the size of the collagen 
gel in each well was evaluated. *P<0.05 vs. control. One-way ANOVA followed by the 
Dunnett’s multiple comparisons test. n=4. (F) Schematic diagram of subcutaneous injection of 
Matrigel solution including DiI-labelled ESCs together with differentiation induction reagents 
into 8-week old C57BL/6J mice. (G) Following 14-day induction by COMP (10 g/ml) or 
PDGF-BB (10 ng/ml) in Matrigel plugs in mice, cross-sections of isolated plugs were 
analyzed through immunofluorescent staining of calponin. Scale bar, 10 μm.  
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Fig. 2. Endogenous COMP is involved in the process of differentiation of ESCs into 
VSMCs. Cell culture dishes were pre-coated with 0.5 ml of Tris-buffered saline containing 10 
µg/ml of mouse collagen IV or 1% of gelatin per cm
2
 area at room temperature overnight. 
Undifferentiated ESCs (2×10
5
 cells per 60 mm dish) were seeded on mouse-collagen 
IV-coated dishes in differentiation medium for differentiation into VSMCs. For PDGF-BB 
and TGF- induction, undifferentiated ESCs were seeded on 1% gelatin-coated dishes in 
differentiation medium followed by PDGF-BB (10 ng/ml) or TGF- (10 ng/ml) treatment. 
(A-C) Representative western blot analysis and quantification of COMP expression during 
ESC differentiation induced by collagen IV (A, 10 g/ml), PDGF-BB (B, 10 ng/ml) or TGF- 
(C, 10 ng/ml). GAPDH was used as the internal control. Data are presented as the mean ± 
SEM from three independent experiments. *P<0.05 vs. 0 day. One-way ANOVA followed by 
the Dunnett’s multiple comparisons test.  (D-E) ESCs were infected with lentivirus encoding 
control or COMP shRNA. Following differentiation induced by 7-day treatment of collagen 
IV (D, 10 g/ml) or PDGF-BB (E, 10 ng/ml), western blotting was performed to evaluate 
COMP, -SMA, calponin and SM22α expression. GAPDH was used as the loading control. 
Quantification of protein expression was from three independent experiments. Data are 
presented as the mean ± SEM. *P<0.05 vs. control shRNA, two-tailed paired Student’s t-test.  
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Fig. 3. Notch signaling mediates COMP-induced ESC differentiation into VSMCs. (A) 
Volcano plots of genes in RNA-Sequencing between ESCs and COMP (10 
g/ml)-differentiated cells (3 days). Blue plots indicate the downregulated genes, and red 
plots indicate the upregulated genes. (B) Heatmap comparative analysis of genes related to 
Notch, TGF, PDGF-BB and integrin signals between ESCs and COMP (10 
g/ml)-differentiated cells (3 days). (C) Representative western blot analysis and 
quantification of -SMA, calponin and SM22α in ESCs seeded on the plates coated with 
COMP (10 g/ml) in the absence or presence of DAPT (10 μM) for 7 days. GAPDH was 
applied as the loading control. Vehicle represents DMSO applied as solvent control. Data are 
presented as the mean ± SEM from three independent experiments. *P<0.05 vs. vehicle. 
Two-tailed paired Student’s t-test. (D) ESCs were induced to differentiate with or without 
treatment of COMP (10 g/ml) in the absence or presence of DAPT (10μM) for 7 days. 
Vehicle represents DMSO applied as a solvent control. Differentiated cells were harvested 
and mixed with ice-cold collagen gel solution in a volume ratio of 1:4. Twenty-four hours 
after collagen polymerization, the size of the collagen gel in each well was evaluated. Data 
are presented as the mean ± SEM from three independent experiments. *P<0.05, one-way 
ANOVA followed by the Dunnett’s multiple comparisons test. (E) Representative western blot 
analysis and quantification of -SMA, calponin and SM22α in ESCs infected with GFP or 
dnMAML lentivirus seeded on the plates coated with COMP (10 μg/ml) for 7 days. 
GFP-encoded lentivirus was applied as control. Data are presented as the mean ± SEM from 
three independent experiments. *P<0.05 vs. control. Two-tailed paired Student’s t-test. (F) 
Representative western blot analysis and quantification of cleaved Notch1, -SMA, calponin 
and SM22α in aortas from 8-week old WT and COMP-/- mice. Data are presented as the mean 
± SEM. *P<0.05 vs. control. Two-tailed unpaired Student’s t-test. n=6.   
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Fig. 4. COMP directly activates Notch1 signaling. (A) Representative western blot analysis 
and quantification of -SMA, calponin and SM22α expression in ESCs infected with 
lentivirus encoding control shRNA, Notch1 shRNA, Notch2 shRNA or Notch3 shRNA and 
then induced by COMP to differentiate for 7 days. Data are presented as the mean ± SEM 
from three independent experiments. *P<0.05 vs. control shRNA, one-way ANOVA followed 
by the Dunnett’s multiple comparisons test. (B) Representative western blot analysis and 
quantification of cleaved Notch1 expression in ESCs seeded on COMP-coated plates at 
different time points. Data are presented as the mean ± SEM from three independent 
experiments. *P<0.05 vs. 0 hour. One-way ANOVA followed by the Dunnett’s multiple 
comparisons test. (C) Luciferase activity assay of 293A cells transfected with 4×CBF1-Luc 
together with pcDNA3.1-COMP, pcDNA3.1-Notch1 or pcDNA3.1-Jagged1. β-Galactosidase 
was co-transfected as the internal control. *P<0.05, data are presented as the mean ± SEM. 
One-way ANOVA followed by the Dunnett’s multiple comparisons test. Three independent 
experiments were performed in triplicate. (D) Representative western blot and quantification 
of cleaved Notch1 in 293A cells transfected with pcDNA3.1-COMP, pcDNA3.1-Notch1 or 
pcDNA3.1-Jagged1. *P<0.05, data are presented as the mean ± SEM. One-way ANOVA 
followed by the Dunnett’s multiple comparisons test. Three independent experiments were 
performed in triplicate. (E) Twenty-four-well plates were pre-coated with 0.5 ml of 
Tris-buffered saline containing various concentrations of mouse collagen IV or mouse COMP 
per cm
2
 area at room temperature overnight. 293A cells transfected with 4×CBF1-Luc and 
pcDNA3.1-Notch1 were seeded on the precoated plates for 48 hours. Luciferase activity was 
measured to indicate Notch1 activation. β-Galactosidase was co-transfected as the internal 
control. 293A cells seeded on the plates without coating served as control. *P<0.05, data are 
presented as the mean ± SEM. One-way ANOVA followed by the Dunnett’s multiple 
comparisons test. n=4.  
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Fig. 5. COMP directly interacts with Notch1. (A-B) Coimmunoprecipitation (Co-IP) of 
COMP and Notch1 in ESC-differentiated cells (A) and COS-7 cells overexpressing COMP 
and Notch1 (B). Rabbit IgG was used as a negative control for IP. (C) Schematic illustration 
of COMP constructs used to map the corresponding domains (N-terminus, EGF, Type III, and 
C-terminus). (D) Representative western blot of Notch1 immunoprecipitated from the lysates 
of COS-7 cells overexpressing Notch1 and Flag-fused COMP construct domains by anti-Flag 
antibody. Mouse IgG was served as a negative control for IP. (E) Schematic illustration of 
Notch1 extracellular EGF constructs. (F-G) Mammalian two-hybrid analysis of interaction 
between the COMP N-terminal domain and the Notch1 EGF domain. Luciferase activity 
assay of 293A cells transiently transfected with various domains of Notch1 EGF repeats 
subcloned into the pBIND vector, together with the N-terminal domain of COMP subcloned 
into the pACT vector. Data are presented as the mean ± SEM. *P<0.05 vs. vector. One-way 
ANOVA followed by the Dunnett’s multiple comparisons test. Three independent experiments 
were performed in triplicate.  
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Fig. 6. The COMP N-terminal domain activates Notch1 signaling and guides ESC 
differentiation towards VSMCs. (A) Representative western blot analysis and quantification 
of cleaved Notch1 in ESCs infected with GFP or COMP N-terminal domain lentivirus. 
GFP-encoded lentivirus was applied as a control. Data are presented as the mean ± SEM from 
three independent experiments. *P<0.05 vs control. Two-tailed paired Student’s t-test. (B) 
Real-time PCR of Hes1, Hey1 and Hey2 in ESCs infected with control or COMP N-terminal 
domain lentivirus. Data are presented as the mean ± SEM. *P<0.05 vs control. Two-tailed 
paired Student’s t-test. Three independent experiments were performed in duplicate. (C) 
Representative western blot analysis and quantification of -SMA, calponin and SM22α  
expression in ESCs infected with lentivirus encoding COMP N-terminal domain or seeded on 
COMP-coated plates for 7 days. Data are presented as the mean ± SEM from three 
independent experiments. *P<0.05 vs. control. One-way ANOVA followed by the Dunnett’s 
multiple comparisons test. (D-E) Immunofluorescent staining of calponin (D) and SM22 (E) 
in undifferentiated ESCs and ESCs overexpressing the N-terminal domain of COMP for 7 
days. Scale bar, 20 m. 
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Highlights: 
 COMP guides ESC-VSMC differentiation dependent on Notch1 activation. 
 COMP directly activates Notch1 signaling. 
 COMP N-terminus directly interacts with the EGF11-12 domain of Notch1. 
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